TY - JOUR AU - Hodi, F. S. AU - O’Day, S. J. AU - McDermott, D. F. PY - 2010 DA - 2010// TI - Improved survival with Ipilimumab in patients with metastatic melanoma JO - N Engl J Med VL - 363 UR - https://doi.org/10.1056/NEJMoa1003466 DO - 10.1056/NEJMoa1003466 ID - Hodi2010 ER - TY - JOUR AU - Postow, M. A. AU - Sidlow, R. AU - Hellmann, M. D. PY - 2018 DA - 2018// TI - Immune-related adverse events associated with immune checkpoint blockade JO - N Engl J Med VL - 378 UR - https://doi.org/10.1056/NEJMra1703481 DO - 10.1056/NEJMra1703481 ID - Postow2018 ER - TY - JOUR AU - Boutros, C. AU - Tarhini, A. AU - Routier, E. PY - 2016 DA - 2016// TI - Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination JO - Nat Rev Clin Oncol VL - 13 UR - https://doi.org/10.1038/nrclinonc.2016.58 DO - 10.1038/nrclinonc.2016.58 ID - Boutros2016 ER - TY - JOUR AU - Robert, C. AU - Long, G. V. AU - Brady, B. PY - 2015 DA - 2015// TI - Nivolumab in previously untreated melanoma without BRAF mutation JO - N Engl J Med VL - 372 UR - https://doi.org/10.1056/NEJMoa1412082 DO - 10.1056/NEJMoa1412082 ID - Robert2015 ER - TY - STD TI - Robert C, Schachter J, Long GV, et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med. 2015;372:2521-32. ID - ref5 ER - TY - JOUR AU - Gandhi, L. AU - Rodriguez-Abreu, D. AU - Gadgeel, S. PY - 2018 DA - 2018// TI - Pembrolizumab plus chemotherapy in metastatic non-small-cell lung Cancer JO - N Engl J Med VL - 378 UR - https://doi.org/10.1056/NEJMoa1801005 DO - 10.1056/NEJMoa1801005 ID - Gandhi2018 ER - TY - JOUR AU - Leonardi, G. C. AU - Gainor, J. F. AU - Altan, M. PY - 2017 DA - 2017// TI - Safety of programmed Death-1 pathway inhibitors among patients with non-small-cell lung Cancer and preexisting autoimmune disorders JO - J Clin Oncol VL - 77 ID - Leonardi2017 ER - TY - STD TI - Luke JJ, Lemons JM, Karrison TG, et al. Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients with Advanced Solid Tumors. J Clin Oncol 36:1611–1618. ID - ref8 ER - TY - JOUR AU - Ngwa, W. AU - Irabor, O. C. AU - Schoenfeld, J. D. PY - 2018 DA - 2018// TI - Using immunotherapy to boost the abscopal effect JO - Nat Rev Cancer VL - 18 UR - https://doi.org/10.1038/nrc.2018.6 DO - 10.1038/nrc.2018.6 ID - Ngwa2018 ER - TY - JOUR AU - Johnson, D. B. AU - Sullivan, R. J. AU - Ott, P. A. PY - 2016 DA - 2016// TI - Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders JO - JAMA Oncol VL - 2 UR - https://doi.org/10.1001/jamaoncol.2015.4368 DO - 10.1001/jamaoncol.2015.4368 ID - Johnson2016 ER - TY - STD TI - Menzies AM, Johnson DB, Ramanujam S, et al. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann Oncol. 2017;28(2):368–76. ID - ref11 ER - TY - JOUR AU - Bergqvist, V. AU - Hertervig, E. AU - Gedeon, P. PY - 2017 DA - 2017// TI - Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis JO - Cancer Immunol Immunother VL - 66 UR - https://doi.org/10.1007/s00262-017-1962-6 DO - 10.1007/s00262-017-1962-6 ID - Bergqvist2017 ER - TY - JOUR AU - Collins, M. AU - Michot, J. M. AU - Danlos, F. X. PY - 2017 DA - 2017// TI - Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodies JO - Ann Oncol VL - 28 UR - https://doi.org/10.1093/annonc/mdx403 DO - 10.1093/annonc/mdx403 ID - Collins2017 ER - TY - JOUR AU - Zhang, Y. AU - Wang, H. PY - 2012 DA - 2012// TI - Integrin signaling and function in immune cells JO - Immunology VL - 135 UR - https://doi.org/10.1111/j.1365-2567.2011.03549.x DO - 10.1111/j.1365-2567.2011.03549.x ID - Zhang2012 ER - TY - JOUR AU - Sandborn, W. J. AU - Feagan, B. G. AU - Rutgeerts, P. PY - 2013 DA - 2013// TI - Vedolizumab as induction and maintenance therapy for Crohn’s disease JO - N Engl J Med VL - 369 UR - https://doi.org/10.1056/NEJMoa1215739 DO - 10.1056/NEJMoa1215739 ID - Sandborn2013 ER - TY - JOUR AU - Rangwala, S. AU - Tsai, K. Y. PY - 2011 DA - 2011// TI - Roles of the immune system in skin Cancer JO - Br J Dermatol VL - 165 UR - https://doi.org/10.1111/j.1365-2133.2011.10507.x DO - 10.1111/j.1365-2133.2011.10507.x ID - Rangwala2011 ER - TY - JOUR AU - Weber, J. AU - Thompson, J. A. AU - Hanid, O. PY - 2009 DA - 2009// TI - A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma JO - Clin Cancer Res VL - 1 UR - https://doi.org/10.1158/1078-0432.CCR-09-1024 DO - 10.1158/1078-0432.CCR-09-1024 ID - Weber2009 ER - TY - JOUR AU - Abdel-Wahab, N. AU - Shah, M. AU - Lopez-Olivo, M. A. PY - 2018 DA - 2018// TI - Use of immune checkpoint inhibitors in the treatment of patients with Cancer and preexisting autoimmune disease JO - Ann Intern Med VL - 168 UR - https://doi.org/10.7326/M17-2073 DO - 10.7326/M17-2073 ID - Abdel-Wahab2018 ER -